Viz.ai Named to the 2019 CB Insights AI 100 List of Most Innovative Artificial Intelligence Companies

SAN FRANCISCO, Feb. 6, 2019 /PRNewswire/ -- CB Insights today named Viz.ai, Inc. to the third annual AI 100 ranking, showcasing the 100 most promising private artificial intelligence companies in the world.

Through an evidence-based approach, the CB Insights research team selected Viz.ai from over 3,000 companies based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights' algorithm, measures the overall health and growth potential of private companies to help predict a company's momentum.

"After being named to the AI 100 in 2018, last year's honorees raised nearly $4.5B across 45 deals with 6 going on to be valued at $1 billion or more," said CB Insights CEO Anand Sanwal. "The data we compiled on this year's nominees, ranging from their customers to their patents to their CB Insights' Mosaic scores, revealed 100 AI companies that are driving transformation across a number of industries and which are taking on a variety of large societal issues ranging from disaster management to cancer diagnosis to detecting fake news. We expect these companies will see similar levels of momentum and progress in 2019 and are excited to continue to track their progress."

"2018 was a tremendous year of growth for Viz.ai, reaffirming our position as the leader in applied artificial intelligence in healthcare," said Dr. Chris Mansi, Viz.ai CEO. "Being recognized as one of the top AI companies in the world by CB Insights validates our continued efforts in transforming healthcare by utilizing AI to synchronize clinical workflow and improve access to life changing treatments."

Viz.ai's expanding suite of FDA cleared products includes a cloud-based AI system that automatically analyzes medical images for potential large vessel occlusion strokes. It helps synchronize care by enabling better collaboration between clinicians at comprehensive and referral hospitals, ensuring the right patient gets to the right doctor at the right time.

Synchronized care has the potential to improve patient outcomes by speeding patients to treatment and ensuring that the doctor best suited to treat the patient is alerted immediately. Viz LVO was the first computer aided triage software to receive FDA clearance. It provides a platform that can save critical minutes, even hours, in the triage, diagnosis and treatment of stroke and allows specialists to be proactive rather than reactive in their treatment decisions.

Quick facts on the 2019 AI 100:

• As of EOY 2018, these emerging private companies have cumulatively raised $9.4B across 375 deals.
• Ten companies have reached a unicorn valuation of $1B or more.
• Over 680 unique investors from 29 different countries have backed the companies in this year's cohort.
• Over 680 US patent applications have been filed by the AI 100.
• Twenty-five previous honorees were featured on this year's list, in addition to 75 new companies.
• Eight countries are represented on the ranking, and the majority of the companies are based in the United States.

About CB Insights
At CB Insights, we believe the most complex strategic business questions are best answered with facts.  We are a machine intelligence company that synthesizes, analyzes and visualizes millions of documents to give our clients fast, fact-based insights. Serving the majority of the Fortune 100, we give companies the power to make better decisions, take control of their own future, and capitalize on change.

About Viz.ai, Inc.
Viz.ai is the leader in applied artificial intelligence in healthcare. Viz.ai's mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai's flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about potential stroke patients straight to a specialist who can intervene and treat.

In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.

Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Innovation Endeavors and DHVC.

SOURCE Viz.ai